Label Changes for:
Mycamine (micafungin sodium) for injection
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011
Postmarketing Adverse Reactions
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis
- Blood and lymphatic system disorders: disseminated intravascular coagulation